Ridloff Elena 4

What Happened

• Elena Ridloff, a director of Kymera Therapeutics, received a grant/award on 2026-06-24 covering 6,068 derivative shares (reported as a stock option award). The grant price is shown as $0.00, meaning no cash was paid at grant. This is a grant (not a sale) and does not represent an immediate market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed 2026-06-25 (timely filing).
• Transaction type/code: A (grant/award/acquisition) — reported as a derivative (stock option).
• Shares/units: 6,068 underlying shares; acquisition price reported $0.00.
• Vesting: Per footnote, the shares underlying the stock option vest in full upon the earlier of (i) June 24, 2027, or (ii) the date of the next annual meeting of stockholders.
• Shares owned after transaction: Not specified in this filing.
• No 10b5-1 plan, tax withholding, cashless exercise, or late-filing flags noted in the report.

Context

• This is a grant of a derivative award (stock option) that vests in the future — not an immediate purchase or sale. Such grants are common compensation for directors and do not by themselves signal insider buying or selling in the open market.